Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Small molecule ubiquitin ligase modulators for immunotherapy of cancer

Award Number: R43CA213582
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2017
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

Small molecule ubiquitin ligase modulators for immunotherapy of cancer - Abstract An exciting and promising new avenue for cancer treatment is the inhibition of immune evasion – the employment by tumors of various strategies to suppress the host immune system’s ability to recognize and destroy cancer cells. Immunotherapies, including monoclonal antibodies, transplanted stem cells and engineered T-cells, vaccines, cytokines, and T-cell checkpoint blockers have shown efficacy against hematologic and solid tumors. Owing to the complexity of immune evasion, however, combination protocols will likely be needed for optimal therapeutic management. Side effects associated with current immunotherapies, including severe autoimmune disease, also support development of alternative immuno-oncology agents. Thus, there is much interest among biotech and pharmaceutical organizations and academic laboratories to find small molecules that promote anti-tumor immunity. A promising new target is Cbl-b, a RING finger E3-ubiquitin ligase expressed primarily in immune cells and critical to immune suppression in the form of T-Cell anergy induced by TGF-β and regulatory T cells (Treg). Cbl-b ubiquitylates the p85 subunit of PI3K, disrupting its recruitment to CD28 in T cells, and has an inhibitory role in regulating NK cell functions via TAM receptor kinases. Cbl-b-/- mice reject various implanted tumors and significantly delay outgrowth of spontaneous tumors; either knocking out Cbl-b or inhibiting TAM kinases leads to NK cell mediated rejection of metastases. Antitumor activity of Cbl-b-/- mice is attributed to hyperactivated CD8+ T cells and NK cells. Thus, Cbl-b is a well-validated immuno-oncology target and Cbl-b inhibitors are expected to decrease p85 ubiquitylation and TAM receptor kinases, promoting T and NK cell activation. In an HTS campaign using a homogenous TR-FRET based Tyro3 substrate ubiquitylation assay, Progenra discovered novel selective Cbl-b inhibitors and demonstrated efficacy in various cellular models including primary T and NK cells. It is proposed here to conduct hit to lead optimization of Cbl-b inhibitors and evaluate them in biochemical, cellular and genetic models of T- and NK-cell activation. In particular, Cbl-b inhibitors are expected to decrease ubiquitylation of substrates Tyro3 and p85, increase cytokine production (e.g.,,IL-2 and IFN), and activate T and NK cells. Selective Cbl-b inhibitors demonstrating cellular and in vivo proof of concept will enter pre-clinical development in Phase II (chemical optimization, ADME, in vivo efficacy) as clinical candidates for novel immuno-oncology therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	PROGENRA, INC	277 GREAT VALLEY PKWY	MALVERN	PA	19355	CHESTER	USA	Cancer Treatment Research	000	1	3/10/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $224,995 )
2017	2017	PROGENRA, INC	277 GREAT VALLEY PKWY	MALVERN	PA	19355	CHESTER	USA	Cancer Treatment Research	000	1	8/29/2017	NEW	$224,995
														Subtotal = $224,995

Grand Total All Awards = $224,995

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Small molecule ubiquitin ligase modulators for immunotherapy of cancer

Award Number: R43CA213582

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2017

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer